Cervical Cancer Screening During Pregnancy
Yes, it is standard of care to perform cervical cytology (Pap test) during pregnancy if the patient is due for screening based on routine screening intervals, regardless of whether it has been done in the last year. 1
Key Recommendation
Pregnant women should be screened at the same frequency as nonpregnant women 1. This means:
- Ages 21-29 years: Cytology alone every 3 years 2
- Ages 30-65 years: Cytology plus HPV co-testing every 5 years (preferred) OR cytology alone every 3 years (acceptable) 2
Clinical Reasoning
The guideline evidence is clear and consistent across multiple CDC STD Treatment Guidelines (2010) that pregnancy does not alter the screening schedule 1. If a pregnant patient is due for routine screening based on standard intervals, the Pap test should be performed during pregnancy.
Important technical considerations:
- Use a swab and Ayre's spatula for collection 1
- Cytobrushes are NOT recommended in pregnancy 1
- Liquid-based cytology is acceptable 1
Management of Abnormal Results Differs
While screening frequency remains the same, management of abnormal results is more conservative in pregnancy 2:
- Colposcopy can be deferred until at least 6 weeks postpartum for most abnormalities 3
- Endocervical curettage is unacceptable in pregnant women 3
- For pregnant women with LSIL without CIN 2, postpartum management is advised 2
- Treatment of CIN 1 is not recommended during pregnancy 2
Common Pitfalls to Avoid
Do not skip screening simply because the patient is pregnant - pregnancy represents an important opportunity to screen women who may otherwise be underscreened 4, 5
Be aware of pregnancy-related cytological changes that can mimic abnormalities 6:
- Navicular cells
- Hyperplastic endocervical cells
- Immature metaplastic cells
- Decidual cells or trophoblasts
- These can mimic koilocytosis, adenocarcinoma in situ, or HSIL
Do not use cytobrushes - this is explicitly contraindicated in pregnancy due to risk of bleeding and pregnancy complications 1
Remember that CIN has higher regression rates during pregnancy, particularly CIN 2, with minimal progression risk 6, 7
Clinical Context
Approximately 3% of newly diagnosed cervical cancers occur in pregnant women, and up to 20% of pregnant women may have abnormal Pap results 4. The prevalence of abnormal cytology in pregnancy does not differ from age-matched nonpregnant populations 4. This makes pregnancy an opportune time for screening, especially in populations with poor screening uptake 5.
The bottom line: Follow standard screening intervals during pregnancy, but modify management of abnormal results to be more conservative, deferring invasive procedures until postpartum when feasible.